Market Newsdesk

KB Home Announces the Grand Opening of Camden Courts, Its Latest New-Home Community in Popular Southwest Las Vegas

Homebuilder offers personalized, new homes in a commuter-friendly location priced from the $290,000s

LAS VEGAS–(BUSINESS WIRE)–
KB Home (NYSE: KBH) today announced the grand opening of Camden Courts, a new single-family home community situated in highly desirable Southwest Las Vegas off Blue Diamond Road between South Durango Drive and South Fort Apache Road. Community residents will enjoy the neighborhood’s convenient location just minutes away from Interstate 15, Interstate 215 and the beautiful Mountain’s Edge Regional Park, a fitness-themed recreation area that includes bike paths, exercise stations, multi-use turf fields, shaded picnic facilities, an outdoor climbing experience, meditation garden, 1.5-mile walking trail and sports wall for racquetball, soccer and other sports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005223/en/

The homes at Camden Courts showcase desirable design characteristics like spacious kitchens overlooking large great rooms and expansive bedroom suites with walk-in closets. The community’s two-story floor plans feature up to five bedrooms and four baths, and range in size from approximately 1,400 to 2,400 square feet. The community also offers the KB Home Office, a dedicated room that homebuyers can personalize for the way they work.

“Camden Courts’ convenient location provides easy access to Interstates 15 and 215 for a quick commute to the Las Vegas Strip and area employers,” said Brian Kunec, President and Regional General Manager of KB Home’s Las Vegas and Seattle divisions. “The new community is also close to schools, a variety of shopping, dining and entertainment, and outdoor recreation at Mountain’s Edge Regional Park and Exploration Peak Park. As with other KB Home communities, Camden Courts provides home shoppers the opportunity to purchase a personalized, new KB home at a price that fits their budget.”

KB Home stands out from other homebuilders as the company gives homebuyers exceptional choice and control. KB Home starts by offering a wide variety of homes at an affordable price. From there, the builder gives buyers the ability to personalize their homes from homesites and floor plans to design features. The KB Home team works hand in hand with homeowners every step of the way so they have a real partner in the process.

Every KB home is designed to be ENERGY STAR^® certified thanks to the quality construction techniques and materials utilized that ultimately deliver significant savings on utility bills compared to used homes. Additionally, all new KB homes are designed to deliver an enhanced indoor environment and include high performance ventilation systems, low- or zero-VOC products and other features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards.

The Camden Courts sales office and model home are open for private in-person tours by appointment, and walk-in visits are welcome. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $290,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 42 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR^® certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005223/en/

Craig LeMessurier, KB Home

925-580-1583

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Residential Building & Real Estate Architecture Construction & Property Interior Design

MEDIA:

Logo

Photo

KB Home announces the grand opening of Camden Courts, its latest new-home community in popular Southwest Las Vegas. (Photo: Business Wire)

Albany International Airport Partners With GE to Transform Airport Into Digital Incubator for Safe, Post-Pandemic Air Travel

• GE to support Albany International Airport’s Master Plan to transform airport into digital incubator, contributing cutting edge technology to create safer travel
• Airport signs on as first customer, using GE’s Wellness Trace App to track COVID-19 cleaning protocols
• New AI, machine learning and other digital technologies to be unveiled at the Airport from GE’s Research Lab in the coming weeks

NISKAYUNA, N.Y. & COLONIE, N.Y.–(BUSINESS WIRE)–
Albany International Airport in collaboration with GE (General Electric), have launched the first digitally-focused airport aimed at demonstrating new technologies to make air travel safer in a post-pandemic world. Highlighting today’s announcement is the Airport signing on as the launch customer for GE Aviation’s new Wellness Trace App, which the Airport has been using to track COVID-19 cleaning protocols. In the coming weeks, the Airport and GE will unveil other advanced artificial intelligence, machine learning and other digital technologies being deployed as part of this burgeoning Digital Incubator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005383/en/

“We’re proud to have GE partner with Albany International Airport, as we advance our new and forward-looking Master Plan that will establish a benchmark for the future design and operation of the nation’s airports. The use of GE’s cutting-edge Wellness Trace App is a major first step in our joint efforts to integrate new digital solutions to create safer travel in a post-pandemic world,” said Philip Calderone, CEO of the Albany County Airport Authority.

“It’s exciting that Albany International Airport is partnering with GE on cutting edge technology that may help travelers feel safer since COVID-19 has changed our world,” said Albany County Executive Daniel P. McCoy. “Being able to scan a QR code and know the last time that surface at the airport was cleaned may alleviate some of the stress and uncertainty people are feeling as they venture out and bring back a sense of confidence. Any reassurance we can give people as they travel that they are doing so safely is important.”

“We believe the digital vision Albany International Airport is advancing is exactly the kind of template airports and airlines will need to ensure safe, healthy travel through the COVID-19 pandemic and beyond,” said Andrew Coleman, general manager of GE Aviation’s Digital Group. “We’re proud to have Albany International sign on as our launch customer. The App is helping them closely track COVID-19 cleaning protocols today, with the potential to track other health screening as the Industry and regulators navigate safe travel in a post-pandemic world.”

WELLNESS TRACE APP

GE Aviation officially launched its commercial Wellness Trace App offering in late June 2020, in partnership with TE FOOD and Eurofins. The App, secured by blockchain technology, provides a comprehensive platform for airports and airlines to track COVID-19 screening for both passengers and employees and set protocols for tracking the cleaning of objects in the airport or aboard aircraft to ensure they are regularly disinfected. Albany Airport is GE’s first customer.

The app’s goal is to have the public light the way for safe travel. The vision for the Wellness Trace cleaning use case is to build a community similar to Waze, TripAdvisor, and Yelp. The app will offer the unique ability for the public to provide real time feedback into the cleanliness of their travel experience. For example, if a traveler needs to stop at a rest stop on their way to the airport, they can check Wellness Trace to find a clean one. If travelers need to grab a bite to eat near the airport, they can check Wellness Trace for the cleanest restaurants nearby. While in the airport, travelers can walk with confidence knowing the environment around them is now transparent and they can access cleaning information with just a quick scan from their mobile phone camera. The most exciting part is that travelers get a voice and can become part of a community where their voice will be heard, and the experience is free for the public. Albany Airport will be the first customer added to the Wellness Trace community, but GE Aviation is actively working to onboard many others right now.

Albany Airport initiated a three-month trial, during which its operations staff will use Wellness Trace to track cleaning and sanitation protocols for key areas and objects around the Airport. More than 45 QR barcode stickers have been placed in areas and on objects throughout the Airport. Using the Wellness Trace App from a mobile phone or tablet, operations staff will be able to validate the cleaning of objects by scanning each QR barcode.

Passengers will be able to simply scan the QR barcode stickers with their mobile device and receive an instant status update for when a given object or area was last cleaned.

Following the three-month trial, GE Aviation and Albany Airport officials will review the experience to discuss any updates or improvements that could be made to App. They also will discuss the feasibility of expanding use of the App for health screening.

Wellness Trace is part of GE’s blockchain solutions portfolio that is expanding its definition of safety in the future by offering food traceability solutions, fuel assurance solutions, and maintenance solutions. For more information check out www.geaviation.com/wellnesstrace

New Digital Incubator Technologies to be added by GE Research

In the following weeks, GE will introduce new digital technologies to test and trial from its Research Lab in Niskayuna, NY. These advanced technologies involving the use of AI, machine learning and predictive analytics and modeling studies will help the Airport stay ahead of changes it needs to make to ensure the safest possible footprint as air travel makes a gradual return to pre-pandemic levels. The Airport will provide a real-time environment for developing and advancing these technologies.

About Albany International Airport

As the major air center for the Capital Region, Northeastern New York and Western New England, the Albany International Airport offers a wide range of facilities and services. A recently completed multi-million- dollar capital redevelopment project included a new 230,000 square foot terminal, parking garage, air traffic control tower, and cargo facility. The airport has also embarked on a five-year $232 million Capital Plan to improve and maintain safety and to meet the needs of air travelers and air carriers well into the 21st Century.

About GE Aviation

GE Aviation, an operating unit of GE (NYSE: GE), is a world-leading provider of commercial and military jet engines, avionics, digital solutions and electrical power systems for aircraft. GE is the world’s Digital Industrial Company, transforming industry with software-defined machines and solutions that are connected, responsive and predictive. With people, services, technology and scale, GE delivers better outcomes for customers by speaking the language of industry. www.geaviation.com/digital

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005383/en/

Todd Alhart, GE Research

t. 1 518 387 7914 [email protected]

Jennifer Villarreal, GE Aviation

t. 1 616 241 8643 [email protected]

 

 

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: General Health Infectious Diseases Health Transportation Travel

MEDIA:

Logo

Photo

Albany Airport launches GE’s Wellness Trace app for COVID-19 cleaning protocols. (Graphic: Business Wire)

BBTV Puts Independent Content Owners Back in Control of Their Content with Powerful Enterprise Grade Content Management Solutions

• BBTV’s Content Management Plus Solution helps manage unauthorized fan uploaded copies of content. This solution was previously available to large content owners such as the National Basketball Association and Sony Pictures.
• BBTV is making its Content Management Solution available to independent content owners of all sizes and genres at scale. Since being launched in pilot form for independent content owners a few months ago, it is already generating billions of monthly incremental views.
• Both enterprise and independent content owners benefit from a greater understanding of their digital fan base, while also benefiting from a new revenue stream.

VANCOUVER, British Columbia–(BUSINESS WIRE)–
BBTV Holdings Inc. (TSX: BBTV), a media tech company that uses technology enabled solutions to help content owners become more successful, today announced the expansion of the company’s Content Management Plus Solutions to individual content owners at scale. BBTV’s Content Management Solutions help manage fan uploaded copies of content to put content owners back in control of their IP, while also creating a new revenue stream for the content owners and BBTV. Enterprise media clients utilising the Content Management Solution include the National Basketball Association (NBA) and Sony Pictures. This is part of BBTV’s Plus Solutions that provide higher margins and enhanced value-adds for BBTV and its partners.

BBTV is making its Content Management Solution available to independent content owners of all sizes and genres. Since being launched in pilot form for independent content owners a few months ago, it is already generating billions of monthly incremental views. This powerful solution is already being used by existing BBTV independent content owner partners such as Brandon Rogers, a comedic genius whose YouTube channel is dedicated to the dark humour in ordinary American life, Family Fun Pack, a fun-loving family with six digital channels featuring popular family friendly content, Kwebbelkop, the 24th largest Gaming creator on YouTube in the United States, and Sam the Cooking Guy who has become a household name in the digital culinary world with his no-nonsense approach to cooking which encourages chefs of all ages to get in the kitchen.

“Content viewership continues to grow exponentially and it’s important that all creators of content, both global media enterprises and independent content owners of all sizes, have the tools to control and manage their fan uploaded content. We’re here to help them protect their IP and ensure they are not leaving money on the table,” comments Shahrzad Rafati, Chairperson and CEO, BBTV. “Our platform enables us to provide scalable solutions to content owners and migrate them from Base to higher margin Plus Solutions without friction. We love empowering our content owners with more tools and capabilities that amplify their success and grow their business.”

For further information please visit bbtv.com

About BBTV

BBTV is a media and technology company headquartered in Vancouver, Canada. BBTV is an enabling platform with a stated mission of advancing the world through the democratization of content. From individual content creators to global media companies, BBTV monetizes the media of content owners through end-to-end management, distribution and monetization solutions, powered by its innovative VISO Platform, including related proprietary technology, while allowing content owners to focus on their core competency – content creation. In June 2020, BBTV had the second most unique monthly viewers among digital platforms with 596 million globally, who consumed more than 54 billion minutes of video content, the most among media companies.* www.bbtv.com

*Calculations and classifications made by BBTV based on data from Comscore contained in Comscore’s “Top 12 Countries = June 2020 comScore Video Metrix Media Trend – Multi-Platform – Top 100 Video Properties Report”.

This press release contains forward looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events including the expected success and strong results of BBTV’s Content Management Solutions. Forward looking information is based on a number of assumptions, including but not limited to assumptions regarding the changes and trends in our industry or the global economy (such as, but not limited to, continued growth in viewership of content), that are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward looking information. Such risks and uncertainties include, but are not limited to the factors discussed under “Risk Factors” in the final prospectus of the Company dated October 22, 2020 filed on sedar at www.sedar.com. The Company does not undertake any obligation to update such forward looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

BBTV-C

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005446/en/

Media

Dan Gamble

Head of PR & Corporate Communications

[email protected]

+1778 873 0422

Ashley Buck

PR and Corporate Communications Specialist

[email protected]

+17788751346

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Entertainment Technology General Entertainment TV and Radio Other Technology Networks

MEDIA:

Logo

Altria Announces Conversion of Its Non-Voting Shares in JUUL; Does Not Intend to Exercise Governance Rights Pending FTC Litigation Outcome

RICHMOND, Va.–(BUSINESS WIRE)–
Altria Group, Inc. (Altria) (NYSE:MO) announces today that it has elected to convert its non-voting shares in JUUL Labs, Inc. to voting shares, pursuant to its December 2018 investment in JUUL. Altria does not currently intend to exercise its additional governance rights obtained upon conversion, including the right to elect directors to JUUL’s board, or to vote its JUUL shares other than as a passive investor, pending the outcome of the U.S. Federal Trade Commission (FTC) litigation.

As previously disclosed, Altria expects to account for its investment in JUUL under the fair value option. Under this option, Altria’s consolidated statement of earnings will include any cash dividends received from its investment in JUUL as well as any changes in the fair value of the investment, which will be calculated quarterly. Altria intends to treat quarterly changes in the fair value of the investment as a special item and exclude those changes from its adjusted diluted earnings per share.

Background

In December 2018, Altria made a minority investment in JUUL. In exchange for the investment, Altria received a 35% economic interest in JUUL through non-voting shares, with their conversion to voting shares contingent on antitrust clearance (as that term is defined in the Altria/JUUL purchase agreement). Under revised agreement terms announced in January 2020, Altria can designate two representatives to JUUL’s board of directors.

In April 2020, the FTC filed an administrative complaint challenging Altria’s minority investment in JUUL. Altria believes it has a strong defense and intends to vigorously defend its investment.

Altria’s Profile

Altria’s wholly owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria owns an 80% interest in Helix Innovations LLC (Helix). Altria holds equity investments in Anheuser-Busch InBev SA/NV (ABI), JUUL Labs, Inc. (JUUL) and Cronos Group Inc. (Cronos).

The brand portfolios of Altria’s tobacco operating companies include Marlboro^®, Black & Mild^®, Copenhagen^®, Skoal^® and on!^®. Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle^®, 14 Hands^® and Stag’s Leap Wine Cellars^™, and it imports and markets Antinori^®, Champagne Nicolas Feuillatte^™ and Villa Maria Estate^™ products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission.

More information about Altria is available at altria.com and on the Altria Investor app, or follow Altria on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005602/en/

Altria Client Services

Investor Relations

(804) 484-8222

Altria Client Services

Media Affairs

(804) 484-8897

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Professional Services Retail Other Retail Wine & Spirits Legal Tobacco

MEDIA:

Logo

DJO® Acquires STAR® Ankle and Finger Arthroplasty Systems

Acquisition adds two new and rapidly growing segments to surgical portfolio

DALLAS–(BUSINESS WIRE)–
DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced that it has completed the acquisition of total ankle and finger arthroplasty product lines from international medical technology company Stryker.

The acquisition includes the STAR® total ankle arthroplasty system, a preferred technology worldwide because of its deep and leading clinical outcomes research,^1-9 along with Silicone, Surface Replacement (SR) and TACTYS® finger joint arthroplasty products, one of the world’s most comprehensive finger joint arthroplasty portfolios.

Ankle replacements in the U.S. more than doubled last year, in part because ankle implants are becoming the treatment of choice over fusion surgery.¹⁰ The STAR ankle is a mobile-bearing total ankle replacement in the U.S. market approved for uncemented use, making it a preferred choice for surgeons and patients who want to help restore mobility.

“Ankle and finger arthroplasty are two fast-growing arthroplasty segments, and this acquisition reflects DJO’s focus on providing market-leading solutions to meet the greater needs of surgeons and their patients,” said Brady Shirley, CEO of DJO®. “This expansion allows us to address a larger patient population and enhances our goal of helping patients return to an active lifestyle.”

STAR System

STAR is one of the first total ankle replacement systems in the market and carries a substantial amount of clinical data over many years demonstrating strong performance.^1-9 Intended for use to replace a painful arthritic ankle joint due to osteoarthritis, post-traumatic arthritis or rheumatoid arthritis, STAR’s modular components and positional forgiveness allow for 225 patient-matched configurations with just one surgical technique.

Finger Joint Arthroplasty

The Silicone, Surface Replacement (SR) and TACTYS finger joint arthroplasty portfolio holds a leading global market position with a 20-year clinical history.

• Silicone constrained silicone elastomer joint replacement devices are designed to replace the affected surface of the PIP and MCP hand joints. The arthroplasty devices have a volar hinge axis intended to create an anatomical balance between the flexor and extensor mechanisms.
• SR semi-constrained implants are designed to replicate the anatomic joint surfaces of the PIP and MCP joints, preserve bone and reduce disruption to the collateral ligament origins and insertions.
• TACTYS implant is a total anatomic gliding and modular prosthesis for (PIP) arthritis.

For more information, visit djoglobal.com/surgical.

About DJO®

DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.

References

1. Jastifer, J., & Coughlin, M. (2014). Long-Term Follow-Up of Mobile Bearing Total Ankle Arthroplasty in the United States. Foot & Ankle International, 143-150.
2. Saltzman, C. L., Mann, R. A., Ahrens, J. E., Amendola, A., Anderson, R. B., Berlet, G. C., . . . Coughlin, M. J. (2009). Prospective Controlled Trial of STAR Total Ankle Replacement versus Ankle Fusion: Initial Results. Foot Ankle Int Foot & Ankle International,30(7), 579-596.
3. Stryker STAR Op Tech STAR-ST-2_Rev-1
4. Gougoulias, N., & Maffulli, N. (2015). History of Total Ankle Replacement in North America. Primary and Revision Total Ankle Replacement, 3-13. doi:10.1007/978-3-319-24415-0_1
5. Mann, J. A., Mann, R. A., & Horton, E. (2011). STAR™ Ankle: Long-Term Results. Foot Ankle Int Foot & Ankle International,32(05), 473-484. doi:10.3113/fai.2011.0473
6. Chao, J., Choi, J. H., Grear, B. J., Tenenbaum, S., Bariteau, J. T., & Brodsky, J. W. (2015). Early radiographic and clinical results of Salto total ankle arthroplasty as a fixed-bearing device. Foot and Ankle Surgery,21(2), 91-96. doi:10.1016/j.fas.2014.09.012
7. Internal document :Includes world-wide implantations of all generations; newest generation has over 30,000 world-wide since 1998-2015.
8. Daniels, T. R., Mayich, D. J., & Penner, M. J. (2015). Intermediate to Long-Term Outcomes of Total Ankle Replacement with the Scandinavian Total Ankle Replacement (STAR). The Journal of Bone and Joint Surgery-American Volume,97(11), 895-903. doi:10.2106/jbjs.n.01077
9. Brodsky, J. W., Polo, F. E., Coleman, S. C., & Bruck, N. (2011). Changes in Gait Following the Scandinavian Total Ankle Replacement. The Journal of Bone and Joint Surgery (American) J Bone Joint Surg Am,93(20). doi:10.2106/jbjs.j.00347
10. American College of Foot and Ankle Surgeons, https://www.foothealthfacts.org/article/ankle-replacement-rapidly-on-the-rise

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005261/en/

Brittany Knudson

760-681-7785

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Surgery Health Medical Devices

MEDIA:

Logo

Zoetis Receives European Commission Marketing Authorization for Librela^® (bedinvetmab)

• The first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs
• Librela works differently from other pain medications, combining one month of pain control and increased mobility, with a proven safety and efficacy profile
• Librela has a unique mode of action, inhibiting Nerve Growth Factor—a key player in osteoarthritis pain

ZAVENTEM, Belgium–(BUSINESS WIRE)–Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Librela (bedinvetmab), the first injectable monoclonal antibody (mAb) therapy approved in the European Union for monthly alleviation of osteoarthritis (OA) pain in dogs. Librela provides veterinarians a new treatment option, which effectively controls OA pain for a month, while also offering a positive safety profile.

Librela is the first-of-its-kind veterinary medicine that contains bedinvetmab, a monoclonal antibody that binds to Nerve Growth Factor (NGF), a key player in OA pain¹ and in doing so reduces pain. It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in its metabolism and elimination from the body; bedinvetmab also produces minimal gastrointestinal (GI) impact.After one injection of Librela, dogs with osteoarthritis exhibited increased mobility and decreased pain.

Untreated OA Pain Can Limit a Dog’s Quality of Life

“My personal experience and clinical research has taught me that OA pain can affect many areas of a pet’s life, including sleep, cognitive function, affect (emotion) and social relationships, among several other factors,” said Dr. Duncan Lascelles, Professor of Surgery and Pain Management at North Carolina State University and Chair of the WSAVA Global Pain Council. “The potential for Anti-NGF therapy to control OA pain is an exciting new development, representing a new therapeutic class, an innovative tool for clinicians working to alleviate OA pain, and a new medicinal innovation. NGF is one of the key factors mediating pain, inducing the release of both proinflammatory mediators and more NGF contributing to a cycle of pain and inflammation. Anti-NGF therapy could be the most exciting therapeutic advance in more than 20 years in veterinary medicine to control osteoarthritis associated pain.”

“We are honored to be granted the first approval of a monoclonal antibody therapy for alleviation of pain for veterinary use,” said Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis. “As a leader in innovation for Animal Health, we are once again using our science and understanding of customer needs to find solutions that can improve the health, well-being and quality of life for pets.”

According to Dr. Knupp, this innovation results from a deeper scientific understanding of the mechanisms of osteoarthritis pain. “Veterinarians have told us that OA remains one of the diseases that affects dogs’ quality of life the most. This first-in-class medicine gives veterinarians effective, safe options to alleviate pain for canine patients, and I am very proud of the breakthrough treatment our Zoetis team has developed,” said Dr. Knupp. “Librela joins Zoetis’ Trocoxil^® and Rimadyl^® as part of the company’s portfolio of treatment options for canine patients with osteoarthritis.”

Bedinvetmab administered as monthly injections during the pivotal field study (three-month placebo-controlled, followed by six months continuation therapy), demonstrated a reduction in osteoarthritis pain as compared to placebo-controlled dogs. Furthermore, this pain reduction was maintained throughout the six-month continuation study, demonstrating sustained efficacy of bedinvetmab for at least nine months. Mild reactions at the injection site (e.g. swelling and heat) may uncommonly be observed. In a subset of dogs included in a single-arm continuation study lasting up to nine months, no loss of efficacy or change in the safety profile were identified. Librela is generally well-tolerated at the recommended dose, and no additional side effects were observed at overdose.

About Librela^® (bedinvetmab)

Bedinvetmab is a monoclonal antibody (mAb) designed for dogs. It neutralizes Nerve Growth Factor (NGF), a key player involved in osteoarthritis in dogs, and in doing so reduces pain. Since bedinvetmab is an antibody it is eliminated by the body similar to endogenous proteins, with minimal involvement of the liver or kidneys. Librela has demonstrated efficacy in lowering canine pain for up to nine months in clinical studies.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, expectations regarding products, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

¹ Schmelz, M., Mantyh, P., Malfait, A.M., Farrar, J., Yaksh, T., Tive, L. and Viktrup, L., 2019. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain, 160(10), p.2210.

ZTS-PS

ZTS-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005321/en/

Media Contact:

Anne-France Quentric

+32 227468311 (o)

[email protected]

Investor Contact:

Steve Frank

1-973-822-7141 (o)

[email protected]

KEYWORDS: Belgium Europe United States North America New Jersey

INDUSTRY KEYWORDS: Consumer Health Pets Veterinary Pharmaceutical

MEDIA:

Logo